Antibiotic resistance and siderophores production by clinical *Escherichia coli* strains

MOHAMED T. KHAZAAL [1], HODA H. EL-HENDAWY [1] *, MONA I. MABROUK [2],
AHMED H. I. FARAAG [1], MARWA R. BAKKAR [1]

[1] Botany and Microbiology Department, Faculty of Science, Helwan University, Cairo, Egypt

[2] National Organization for Drug Control and Research, Cairo, Egypt

Abstract

The phenomenon of antibiotic resistance has dramatically increased in the last few decades, especially in enterobacterial pathogens. Different strains of *Escherichia coli* have been reported to produce a variety of structurally different siderophores. In the present study, 32 *E. coli* strains were collected from different clinical settings in Cairo, Egypt and subjected to the antibiotic susceptibility test by using 19 antibiotics belonging to 7 classes of chemical groups. The results indicated that 31 strains could be considered as extensively drug-resistant and only one strain as pan drug-resistant. Siderophores production by all the tested *E. coli* strains was determined qualitatively and quantitatively. Two *E. coli* strains coded 21 and 49 were found to be the most potent siderophores producers, with 79.9 and 46.62%, respectively. Bacterial colonies with cured plasmids derived from strain 49 showed susceptibility to all the tested antibiotics. Furthermore, *E. coli* DH5α cells transformed with the plasmid isolated from *E. coli* strain 21 or *E. coli* strain 49 were found to be susceptible to ansamycins, quinolones, and sulfonamide groups of antibiotics. In contrast, both plasmid-cured and plasmid-transformed strains did not produce siderophores, indicating that the genes responsible for siderophores production were located on plasmids and regulated by genes located on the chromosome. On the basis of the obtained results, it could be concluded that there is a positive correlation between antibiotic resistance, especially to quinolones and sulfonamide groups, and siderophores production by *E. coli* strains used in this study.

Key words: siderophores, *Escherichia coli,* clinical strains, antibiotic susceptibility

Introduction

Escherichia coli is a gram-negative bacterial species that belongs to the *Enterobacteriaceae* family. This species includes both commensal and pathogenic strains (Leimbach et al., 2013). Pathogenic *E. coli* can cause a broad spectrum of diseases in humans (Belanger et al., 2011). *E. coli* is one of the most common pathogens that causes both community-acquired and hospital-acquired infections, including infections of the urinary and gastrointestinal tracts, peritonitis, meningitis, sepsis, and medical device-associated infections (Paterson, 2006; Mathlouthi et al., 2016). Infections caused by *E. coli* are associated with significant morbidity and mortality (Mathlouthi et al., 2016), and *E. coli* accounts for up to 90% of all urinary tract infections (UTIs) (Dromigny et al., 2005).

E. coli plays an important role in resistant bacterial populations, and it is widely used as a bio-indicator for monitoring antimicrobial resistance because of its presence in a wide range of hosts and its ability to gain resistance easily (Tadesse et al., 2012). The occurrence and susceptibility profile of *E. coli* shows not only substantial geographic variations but also significant differences in inhabitance and environmental ambience (Von Baum and Marre, 2005). Treatment of infections caused by pathogens such as *E. coli* and *Klebsiella pneumoniae* is threatened by the emergence and increase in antimicrobial resistance associated with genetic mobile elements such as plasmids that may also contain virulence genes (Hennequin and Robin, 2016). These bacterial species are

proficient pathogens because they are virulent, antibiotic resistant, and epidemic in nature (Wang et al., 2014).

Pathogenic *E. coli* isolated from different clinical infections possesses a broad range of virulence-associated factors, including toxins, adhesions (fimbriae), lipopolysaccharides, polysaccharide capsules, proteases, and siderophores (salmochelin, yersiniabactin, and aerobactin), which are encoded by pathogenic islands and other mobile genetic elements (Bashir et al., 2012; Pitout, 2012; Wang et al., 2014).

Because of diversity in the mechanism of acquisition of resistance and virulence factors of the strains, the correlation between resistance and virulence is a complex issue and is poorly understood (da Silva and Mendonça, 2012; Ramirez et al., 2014; Hennequin and Robin, 2016). Knowledge and understanding of correlations between antibiotic resistance, virulence factors, and phylogenetic background would therefore be helpful and enable antibiotic treatment of several infections (Wang et al., 2014). The present study was conducted to determine whether siderophores production by *E. coli* strains has a role in its antibiotic resistance.

Materials and methods

Bacterial strains

Thirty-two clinical *E. coli* strains were collected from different clinical settings in Cairo, Egypt (12 strains were obtained from Al Salam International Hospital, 9 from Ain Shams Specialized Hospital, 4 from the National Cancer Institute, 3 from Demerdash Hospital, and 1 strain from Samir Shaker Laboratory) and used in this study. Of these 32 strains, 28 were isolated from urine, 2 from sputum, 1 from pus, and 1 from wound. These strains were grown at 37°C for 24 h on different selective and differential ready-to-use dehydrated media to confirm their identification. These media included eosin methylene blue agar (EMBA), brilliant green agar (BGA) (Lab M, United Kingdom), MacConkey agar (MACA), Sorbitol MacConkey agar (SMACA) (HiMedia Laboratories, India), and violet red bile agar (VRBA) with MUG (Biolife, Italia).

Screening for antibiotic susceptibility

Antibiotic susceptibility of the 32 clinical *E. coli* strains was tested using the Kirby-Bauer disc diffusion method (Bauer et al., 1966) with different antibiotic discs. These antibiotics (Bioanalyse, Turkey) included gentamycin (GMN) 10 μg, kanamycin (KAN) 1 mg, rifampicin (RD) 5 μg, ampicillin (AMP) 10 μg, amoxycillin (AML) 10 μg, penicillin (P) 10 U, cefoxitin (FOX) 30 μg, cephalexin (CL) 30 μg, ceftriaxone (CRO) 30 μg, cefixime (CFM) 5 μg, cefaclor (CEC) 30 μg, cefoperazone (CFP) 75 μg, cefadroxil (CFR) 30 μg, cefoperazone/sulbactam (CFS) 75/30 μg, cefuroxime sodium (CXM) 30 μg, vancomycin (VA) 30 μg, norfloxacin (NOR) 10 μg, ofloxacin (OFX) 5 μg, and sulfamethoxazole/trimethoprim (SXT) 25 μg. All data were evaluated according to CLSI criteria (CLSI, 2019).

Siderophores production

All strains were screened for siderophores production qualitatively according to the method of Alexander and Zuberer (1991). Overnight cultures were grown on Chrome Azurol Sulfonate (CAS) agar plates. A yellow halo surrounding the bacterial colony after 4–5 days of incubation at 37°C indicated positive siderophores production. Siderophores production by *E. coli* strains grown in M9 medium (Maniatis et al., 1982) was also determined quantitatively by using CAS liquid medium according to Schwyn and Neilands (1987) and by the method of Alexander and Zuberer (1991) in which 2-[N-morpholino] ethanesulfonic acid (MES buffer) (Fisher Scientific, Belgium) was used as a buffer solution instead of solution 2 in the original method.

16S rRNA gene sequencing and phylogenetic analysis

The genomic DNA of *E. coli* strains 21 and 49, the most potent siderophores producers, was extracted using the Wizard® Genomic DNA Purification Kit (Thermo Scientific, Lithuania). A PCR thermal cycler (Biometra® cycler personal) was used for 16S rRNA gene amplification under the following programmed conditions: 95°C for 5 min, followed by 35 cycles at 95°C for 1.5 min, 59°C for 1 min, and 72°C for 1.5 min, and a final 10 min extension at 72°C. PCR amplification of the 16S rRNA gene was performed using two universal oligonucleotide bacterial primers, namely 16S rRNA forward primer: 5′-GAG TAA TGT CTG GGA AAC TGC CT-3′, and 16S rRNA reverse primer: 5′-CCA GTT TCG AAT GCA GTT CCC AG-3′. The purified PCR products were sequenced in an automated sequencer (ABI Prism 3730XL, Applied Biosystems, Foster City, CA) at Macrogen Inc., Korea. The sequen-

ces were analyzed using Geneious Pro 8.1.1, and sequence identity search was then performed using BLAST (Altschul et al., 1990). Phylogenetic analysis was performed using the Molecular Evolutionary Genetics Analysis software (Geneious Pro 8.1.1). The phylogenetic tree was constructed using the neighbor-joining tree method (Saitou and Nei, 1987), and the genetic distance model was developed using the Tamura-Nei model (Tamura and Nei, 1993).

Plasmid preparation and curing

Small-scale preparation of plasmids from *E. coli* strains 21 and 49 was performed according to Sambrook et al. (1989). Plasmid curing trials were then performed using different methods (Trevors, 1986), such as growing *E. coli* strains in nutrient broth (NB) at elevated temperatures of 40, 45, and 50°C (their highest sublethal doses) for 24–48 h. The bacterial strains were also grown in NB supplemented with sterilized mitomycin C (15 μg/ml) or sodium dodecyl sulfate (SDS) (10%) at 37°C for 24–48 h. The developed colonies were picked up and streaked on the surface of both LB agar plates (master plates) and LB agar plates supplemented with GMN, AMP, SXT, and CRO. The cured colonies were then screened for antibiotic sensitivity and subjected to qualitative and quantitative assessment of siderophores production.

Bacterial transformation

Bacterial transformation was performed according to Bimboim and Doly (1979). *E. coli* strain DH5α was prepared as competent cells and then transformed with plasmids isolated from *E. coli* strains 21 and 49, individually. Screening for antibiotic susceptibility was performed, and qualitative and quantitative siderophores production by the transformed competent cells was determined as previously described.

Statistical analysis

One-way ANOVA and simple linear regression were used to analyze the data obtained from the study by using GraphPad Prism Version 9.0 for Windows (GraphPad Software Inc., San Diego, CA).

Results

All clinical *E. coli* strains were grown on different selective and differential media. After incubation at 37°C

for 24 h, the growth of the strains appeared as green metallic sheen colonies on EMBA; pink colonies surrounded with precipitation on MACA; yellow to yellow-green colonies surrounded with precipitation on BGA; colorless colonies on SMACA, and colonies that do not fluorescence blue under long wavelength UV light on VRBA with MUG. These observations confirmed that these strains were *E. coli*.

Antibiotic susceptibility of E. coli strains

The 32 clinical *E. coli* strains used in this study were tested for antibiotic susceptibility by using the Kirby-Bauer disc diffusion method. Data presented in Table 1 revealed that 16 of the 32 strains (50%) and numbered (2, 6, 15, 23, 26, 26′, 33, 49, 55, 66, 70, 71, 73, 78, 95, and 117) were found to be resistant to all antibiotic groups. Nine of the remaining strains (28.125%) were resistant to 6 antibiotic groups. Additionally, 6 strains (18.75%) and 1 strain (3.125%) were found to be resistant to 5 and 4 antibiotic groups, respectively. The results also showed that the highest resistance (100%) was observed for ansamycins, cephalosporins, β-lactams, and glycopeptide antibiotics, followed by 84.4 and 81.2% resistance to quinolones and sulfonamide, respectively. However, only one strain (strain number 15) showed complete resistance to aminoglycosides. In addition, 18 strains (56.2%) and 4 strains (12.5%) were resistant to gentamycin and kanamycin, respectively. Statistical analysis of the obtained results by one-way ANOVA showed that the differences were significant at $P < 0.0001$ as shown in supplementary material (Table S1).

Siderophores production

All *E. coli* strains used in this study were qualitatively screened for siderophores production by using CAS agar plates. The presence of yellow halos around the bacterial growth indicated the production of siderophores (Fig. 1). The results revealed that 23 *E. coli* strains produced siderophores based on the differences in the diameters of yellow halos, whereas 9 strains did not show siderophores production. The largest yellow halo was produced by *E. coli* strain 71, whereas the smallest halos were produced by *E. coli* strains 1, 49, 58, and 95. In contrast, none of the *E. coli* strains 6, 22, 23, 26, 66, 70, 81, 101 and 120 produced yellow halos on CAS agar plates. The amount of siderophores produced by *E. coli* strains tested in the present study was also

Table 1. Antibiotic susceptibility pattern of the 32 clinical *E. coli* strains according to CLSI (2019)

Bacterial strains	Chemical group of antibiotics																		
	Aminoglycoside		Ansa-mycins	β-lactams			Cephems									Glyco-peptides	Quinolones		Sulfo-namide
	GMN_{10}	KAN	RD_5	AMP_{10}	AML_{10}	P_{10}	FOX_{30}	CL_{30}	CRO_{30}	CFM_5	CEC_{30}	CFP_{75}	CFR_{30}	$CFS_{75/30}$	CXM_{30}	VA_{30}	NOR_{10}	OFX_5	SXT_{25}
1	I	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	S
2	R	I	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
6	R	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
10	R	I	R	R	R	R	R	R	R	R	R	R	R	R	R	R	S	S	I
15	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
21	S	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
22	I	I	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
23	R	I	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
24	S	I	R	R	R	R	I	R	R	R	R	R	R	R	R	R	S	S	R
25	I	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	S	S	S
26	R	I	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
26′	R	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
29	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	S	S	R
33	R	R	R	R	R	R	I	R	R	R	R	R	R	R	R	R	R	R	R
34	I	I	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
49	R	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R

Table 1 continue

Bacterial strains	Chemical group of antibiotics																		
	Aminoglycoside		Ansa-mycins	β-lactams			Cephems									Glyco-peptides	Quinolones		Sulfo-namide
	GMN$_{10}$	KAN	RD$_5$	AMP$_{10}$	AML$_{10}$	P$_{10}$	FOX$_{30}$	CL$_{30}$	CRO$_{30}$	CFM$_5$	CEC$_{30}$	CFP$_{75}$	CFR$_{30}$	CFS$_{75/30}$	CXM$_{30}$	VA$_{30}$	NOR$_{10}$	OFX$_5$	SXT$_{25}$
52	R	R	R	R	R	R	R	R	R	R	R	S	R	S	R	R	R	R	S
55	R	S	R	R	R	R	I	R	R	R	R	R	R	R	R	R	R	R	R
58	I	S	R	R	R	R	R	R	R	R	R	R	R	I	R	R	R	R	S
65	I	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
66	R	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
70	R	I	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
71	R	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
73	R	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
78	R	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
81	S	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
95	R	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
96	I	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
101	S	I	R	R	R	R	S	R	R	R	R	R	R	R	R	R	S	S	R
117	R	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
120	I	S	R	R	R	R	R	R	R	R	R	I	R	R	R	R	R	R	S
122	S	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R

GMN – gentamycin (10 µg), KAN – kanamycin (1 mg), RD – rifampicin (5 µg), AMP – ampicillin (10 µg), AML – amoxycillin (10 µg), P – penicillin (10 U), FOX – cefoxitin (30 µg), CL – cephalexin (30 µg), CRO – ceftriaxone (30 µg), CFM – cefixime (5 µg), CEC – cefaclor (30 µg), CFP – cefoperazone (75 µg), CFP – cefoperazone (75 µg), CFR – cefadroxil (30 µg), CFS – cefoperazone/sulbactam (75/30 µg), CXM – cefuroxime sodium (30 µg), VA – vancomycin (30 µg), NOR – norfloxacin (10 µg), OFX – ofloxacin (5 µg), SXT – sulfamethoxazole/trimethoprim (25 µg); S – sensitive, I – intermediate, R – resistance

Table 2. Siderophore production by the clinical *E. coli* strains tested in this study

Bacterial strains	Siderophore production					
	Schwyn and Neilands (1987)			Alexander and Zuberer (1991)		
	Ar	As	siderophore production [%]	Ar	As	siderophore production [%]
1	0.619	0.287	53.6	0.697	0.613	12.05
2	0.619	0.276	55.4	0.697	0.572	17.93
6	1.009	1.217	–	0.697	1.066	–
10	1.009	1.155	–	0.697	0.839	–
15	0.977	0.620	36.5	0.697	0.392	43.75
21	0.977	0.866	11.3	0.697	0.140	79.9
22	1.009	1.280	–	0.697	0.611	12.38
23	0.619	0.301	51.37	0.697	0.650	6.74
24	0.977	0.952	2.5	0.697	0.505	27.54
25	1.009	1.077	–	0.697	0.452	35.15
26	0.619	0.311	49.7	0.697	0.446	36.01
26	0.619	0.252	59.28	0.697	0.489	29.84
29	1.009	0.638	36.7	0.697	0.700	–
33	0.977	0.542	44.5	0.697	0.590	15.35
34	0.977	0.930	4.8	0.697	0.576	17.36
49	0.619	0.253	59.1	0.697	0.372	46.62
52	0.619	0.420	32.1	0.697	0.628	9.89
55	1.009	0.646	35.97	0.790	0.465	41.26
58	0.977	0.538	44.9	0.697	0.593	14.92
65	1.009	0.598	40.7	0.697	0.600	13.9
66	1.009	0.738	26.8	0.697	0.652	6.45
70	0.977	0.810	17	0.697	0.640	8.17
71	1.009	1.196	–	0.697	0.541	22.38
73	0.977	0.572	41.4	0.697	0.708	–
78	0.619	0.325	47.4	0.697	0.610	12.48
81	1.009	1.129	–	0.697	0.444	36.29
95	0.619	0.279	54.9	0.697	0.558	19.94
96	1.009	1.145	–	0.697	0.382	45.19
101	0.619	0.270	56.38	0.697	0.751	–
117	1.009	0.809	19.8	0.790	0.643	14.7
120	1.009	1.083	–	0.697	0.595	14.63
122	0.619	0.274	55.7	0.697	0.939	–

As – is the absorbance of sample solution; Ar – is the absorbance of reference solution; sidero-phore production % was determined using the formula [(Ar – As)/Ar] × 100; (–) – indicates no siderophore production

determined quantitatively by using the method of Alexander and Zuberer (1991) with some modification. The obtained results indicated that the highest percentage of the produced siderophores was 79.9% and was shown by

E. coli strain 21, followed by strains 49 and 96 with 46.62 and 45.19% siderophores unit, respectively. The lowest percentage of siderophores was produced by *E. coli* strains 23 and 66 with 6.74 and 6.45% sidero-

Fig. 1. Yellow halo formed around the bacterial growth indicating siderophore production by clinical *E. coli* strains; diameter of the yellow halo around the bacterial growth was measured in mm after incubation of plates at 37°C for 2 days; *E. coli* strains: A) 58, B) 1, C) 49, D) 29, E) 55 and F) 26

phores unit, respectively. In contrast, no siderophores were detected from *E. coli* strains 6, 10, 29, 73,101, and 122 by this method (Table 2). Statistical analysis of siderophores production quantitatively by clinical *E. coli* strains by using simple linear regression showed that the differences were not significant at *P* = 0.1280, as shown in supplementary material (Table S2).

Analysis of 16S rRNA gene sequences

Based on the alignment of 16S rRNA gene sequences from the GenBank database, the 16S rRNA gene sequences of the tested strains showed the highest similarity to that of *E. coli* (Fig. 2). Strain 21 was most similar to *E. coli* JCM 1649 with 98.3% identity, whereas strain 49 was most similar to *E. coli* g8 with 97.4% identity.

Plasmid curing

E. coli strains 21 and 49 were tested for harboring of plasmids by small-scale preparation of plasmid and agarose gel electrophoresis. The obtained results revealed that plasmids were detected in both samples, wherein 2 or 3 bands represented the different forms of plasmids such as supercoiled, nicked relaxed, and linear forms (Fig. 3). To obtain plasmid-cured *E. coli* strains, strains 21 and 49 were grown in LB broth medium under different curing conditions, as mentioned in Ma-

terials and methods. The obtained results indicated that the absence of plasmid-cured mutants of *E. coli* strain 21. Moreover, the growth of *E. coli* strain 49 in NB overnight at 50°C yielded 10 colonies on the nutrient agar (NA) plate. Of these colonies, only 4 failed to develop on NA plates containing GMN, AMP, SXT and CRO, individually. These colonies were found to be devoid of plasmids (Fig. 4). Moreover, these plasmid-cured strains failed to grow on CAS agar medium, and no siderophores were detected when these strains were grown in M9 medium and assayed for siderophores production by using the modified CAS assay method (Table 3).

Screening for antibiotic sensitivity and siderophores production by transformed E. coli DH5α

E. coli DH5α was transformed with plasmids isolated from both *E. coli* strains 21 and 49, individually. The transformed *E. coli* DH5α colonies were then screened for antibiotic sensitivity and siderophores production qualitatively and quantitatively in the CAS-containing medium. The results showed that *E. coli* DH5α cells transformed with the plasmid isolated from *E. coli* strain 49 were resistant to antibiotics belonging to β-lactams, cephems, and glycolipids. However, *E. coli* DH5α cells transformed with the plasmid isolated from *E. coli* strain 21 were resistant only to antibiotics belonging to β-lactams and cephems (Table 4). Statistical analysis of antibiotic susceptibility of plasmid-cured and plasmid-transformed *E. coli* strains by one-way ANOVA showed that the differences were not significant at *P* = 0.4442, as shown in supplementary material (Table S3). Moreover, native and transformed *E. coli* DH5α cells failed to grow on CAS agar medium, and no siderophores were detected from them using the modified CAS assay.

Discussion

Antibiotics are the most important therapeutic agents used for treating bacterial infections, and therefore, an extensive increase in the incidence of antibiotic-resistant bacteria is a major worldwide concern (Sabtu et al., 2015; Church and McKillip, 2021). Microorganisms acquire drug resistance through various mechanisms such as recombination of foreign DNA in bacterial chromosome, horizontal gene transfer, and alteration in genetic material (Von Baum and Marre, 2005; Kiffer et al., 2007; Pondei et al., 2012).

E. coli plays an important role in resistant bacterial populations, and it is widely used as a bio-indicator for

Fig. 2. Rooted phylogenetic tree showing the relationship of the 16S rRNA gene of strains 21 and 49 and the 16S rRNA gene sequence aligned in MUSCLE (Edgar, 2004); the tree was constructed using the Geneious Tree Builder option (Genetic distance model: Tamura-Nei, tree builder methods: Neighbor-joining, and Outgroup: ECORRD); the tree was rooted with *E. coli* as a member of the *Enterobacteriaceae* family (Drummond et al., 2014)

monitoring antimicrobial resistance because of its presence in many different hosts and its ability to gain resistance easily (Tadesse et al., 2012).

In the present study, 32 clinical *E. coli* strains were tested. These *E. coli* strains were resistant to at least 14 antibiotics out of the 19 drugs tested, which belonged to different chemical groups. Thirty-one strains were classified as extensively drug-resistant (XDR) (*i.e.,* strains susceptible to only one or two antibiotic groups), and only one strain was classified as pan drug-resistant (PDR) (*i.e.,* strains resistant to all antibiotic groups) (Magiorakos et al., 2011). The increased resistance of bacteria to antibiotics could be attributed to the dramatic increase in the consumption of different antibiotics without clinical confirmation (Malik and Bhattacharyya, 2019), in addition to the overuse of antibiotics in animal nutrition (Ma et al., 2021). In Cairo, increased resistance was observed to different antibiotic classes among gram-positive cocci and gram-negative bacilli strains isolated from blood culture (Khalifa et al., 2019; Fahim, 2021).

The antibiotic resistance pattern of the tested *E. coli* strains showed high resistance rates (100%) to antibiotics belonging to β-lactams, ansamycins, glycolipids, and 6 cephem antibiotics; 84.3% resistance to quinolones, and 81.25% resistance to sulfonamides. The strains also showed moderate resistance (56.25%) to GMN and the lowest resistance (12.5%) to KAN–two antibiotics belonging to aminoglycosides. As a comparative study, 50 clinical strains of *E. coli* were isolated from 5 hospitals in Cairo, Egypt during 1999–2000. High and moderate resistance to AML (94%) and GMN (48%), respectively, was recorded (El Kholy et al., 2003). These results agree to a great extent with the results of the present study.

High resistance to AML followed by sulfonamides and low resistance to GMN have been reported in many studies, including some retrospective studies (Moroh et al., 2014; Chakrawarti et al., 2015; Adefisoye and Okoh, 2016; Tajbakhsh et al., 2016). As ampicillin was first introduced in 1961, the long-term use of this antibiotic has been proposed to be responsible for increased resistance (Tadesse et al., 2012). Although resistance to β-lactam antibiotics is mainly attributed to the production of β-lactamases, other mechanisms such as AmpC-type cephalosporinases and changes in porin channels could be involved (Abdallah et al., 2015; Khalifa et al., 2019).

Fig. 3. Agarose gel electrophoresis of the pathogenic *E. coli* strains 21 and 49; plasmid miniprep lane 1 – *E. coli* strain 21; lane 2 – *E. coli* strain 49; lane M – 100-bp molecular DNA marker


Fig. 4. Agarose gel electrophoresis of the pathogenic *E. coli* strain 49; plasmid miniprep lane 1 – native strain; lanes 2, 3, 4, and 5 – colonies grown at 50°C for 24 h and devoid of plasmid; lane M – 100-bp molecular DNA marker

Although sulfonamides were not largely used in the United States, Stockholm, and Sweden, an increased resistance of clinical *E. coli* strains to this antibiotic group was observed over time (Kronvall, 2010). Ali et al. (2014) reported that the highest resistance level of 86.25% (69 of 80 strains) of uropathogenic *E. coli* (UPEC) strains isolated from nonhospitalized patients was recorded against trimethoprim-sulfamethoxazole (TMP-SMZ).

Although quinolones are largely considered as the antibiotic of choice in treating many pathogenic bacterial infections, including UTIs, increased resistance to these newer compounds has been observed (Ali et al., 2014; Khalifa et al., 2019). In another study, 51% (65 of 129) of clinical *E. coli* strains isolated in Poland were resistant to nalidixic acid (quinolone group) (Adamus-Bialek et al., 2013). In Shanghai, the resistance rate of UPEC to quinolones increased from 58.7% in 2008 to 71.2% in 2014 (Wang et al., 2014). Rath and Padhy (2015) studied the antibiotic resistance pattern of 1642 *E. coli* strains to fluoroquinolone antibiotics and reported that 575 of 832 hospital-acquired (HA) and 567 of 810 community-acquired (CA) *E. coli* strains showed resistance. In another study, 58 and 43 strains of 80 biofilm-producing UPEC were resistant to nalidixic acid and norfloxacin (quinolone antibiotics) with the resistance rate of 72.5% and 53.75%, respectively; however, 43 and 26 strains of 50 nonbiofilm producers were resistant to the same anti-

biotics (Tajbakhsh et al., 2016). In the present study, the level of resistance to quinolones was 84.3%, which exceeded the abovementioned findings.

Resistance to quinolones is mainly caused by mutations in the target enzyme DNA gyrase (*gyr A* and *gyr B*) genes in the gram-negative bacteria; however, the plasmid encoding the Qnr protein may also confer resistance against this class of antibiotics (Jacoby, 2005; Leski et al., 2016). In *E. coli*, single-nucleotide polymorphisms (SNPs) are the predominant mechanisms of resistance to antibiotics (Leski et al., 2016; Malekzadegan et al., 2019; Kakoullis et al., 2021).

In the present study, aminoglycosides were found to be the most effective antibiotics relative to the other classes of antibiotics. Shanahan et al. (1993) suggested that the lower resistance rate (7.5%) of *E. coli* isolates to aminoglycosides was attributed to the lower usage of this drug as compared to ampicillin and trimethoprim, which are older and the most widely used antibiotics worldwide. In the United States, Tadesse et al. (2012) conducted a retrospective study for antibiotic resistance change pattern of clinical *E. coli* strains during 1950–2002, and rare gentamycin resistance was observed. However, in Sweden, Kronvall (2010) conducted a survey over the period of 1979 to 2009 and observed a slight increase in resistance to gentamycin in clinical

Table 3. Quantitative assay of siderophores produced by the plasmid-cured strains and the native strain of *E. coli* strain 49 by using the modified CAS assay method

Strain 49		Ar	As	Siderophore unit [%]
Native strain		0.690	0.395	42.75
Cured strains	1	0.690	0.833	–
	2	0.690	0.787	–
	3	0.690	0.791	–
	4	0.690	0.780	–

As – is the absorbance of sample solution, Ar – is the absorbance of reference solution, (–) – indicates no production of siderophores

E. coli strains at the end of the period, although it was increased from 1.42% in 2006 to 2.45% in 2009.

The common resistance mechanism against aminoglycosides in *E. coli* involves the modification of aminoglycosides by aminoglycoside-modifying enzymes. The main enzymes encountered in *E. coli* are aminoglycoside acetyltransferases, phosphotransferases, and nucleotidyl transferases as these enzymes prevent the binding of the drug to ribosomes of the cell (Bodendoerfer et al., 2020; Kakoullis et al., 2021).

The results obtained in the present study indicated that the resistance of *E. coli* strains to the first-generation cephalosporins was 100%, whereas it was 87.5% for second- and third-generation cephalosporins. In a previous study, the resistance rate of 80 clinical *E. coli* strains to the first-, second-, and third-generation cephalosporins was 70, 53.7, and 58.5%, respectively (Ali et al., 2014). Similar findings were reported in India by Rath and Padhy (2015). Resistance to third-generation cephalosporins was also recorded in other investigations (Van Der Steen et al., 2015; Lin et al., 2019; Prasada et al., 2019). Additionally, Gashe et al. (2018) reported that 73% and 65% of the tested clinical *E. coli* isolates were resistant to ceftriaxone and ceftazidime, respectively. Moreover, in another study, none of the 129 clinical *E. coli* strains were resistant to cefuroxime sodium (Woo et al., 2019).

Iron is one of the most important microelements required by all living organisms for various metabolic processes essential for growth and survival (Kramer et al., 2020). Although iron is the fourth element in the earth's crust under aerobic conditions, the bioavailability of iron is extremely restricted where it exists in an insoluble trivalent state as oxides or hydroxides (Emerson et al., 2012). Therefore, under conditions of iron limita-

tions, many microorganisms are induced to produce and secrete low-molecular-weight iron-chelating compounds known as siderophores (Schwyn and Neilands, 1987; Ahmed and Holmström, 2014). Several studies have demonstrated that both gram-negative and gram-positive bacteria synthesize and secrete siderophores into the environment under iron-limited conditions, where they bind ferric iron (Fe III) with high affinity (Saha et al., 2016).

Many commensal *E. coli* strains can produce these virulent-associated siderophores (Searle et al., 2015). Therefore, siderophores can be considered as a putative virulence factor rather than being considered as typical virulent factors directly involved in infection by pathogenic *E. coli* strains, where they contribute to increase in fitness, adaptability, competitiveness, chance of survival, and colonization in human body (Holden and Bachman, 2015). In contrast, other studies have considered siderophores production as a virulence factor in pathogenic bacteria (Vagrali, 2009; Lisiecki, 2013; Hennequin and Robin, 2016) and in particular pathogenic *E. coli*, where siderophores are considered as a target to achieve antibacterial control and restrict bacterial growth (Massip and Oswald, 2020). Enterobactin production was found to play an important role in *E. coli* colonization in the gastrointestinal tract (GIT) (Pi et al., 2012). However, the ability to synthesize additional siderophores such as yersinobactin and salmochelin is generally correlated with virulence, especially for extraintestinal pathogenic *E. coli* (ExPEC) (Garénaux et al., 2011; Sarowska et al., 2019). This was also reported in other studies. Searle et al. (2015) found that plant-associated *E. coli* strains isolated from leafy green vegetables produced significantly less amount of siderophores than fecal-associated strains. In contrast, 97.5% of 160 UPEC strains were found to be positive siderophores producers as compared to only 4% of 50 fecal-associated strains, suggesting the frequent but unconfirmed role of siderophores in pathogenicity (Vagrali, 2009).

In the present study, the production of siderophores by the 32 clinical *E. coli* strains was determined both qualitatively using the CAS agar medium (Alexander and Zuberer, 1991) and quantitatively using the CAS assay solution method of Schwyn and Neilands (1987) and the modified CAS assay solution method of Alexander and Zuberer (1991). In the qualitative detection of siderophores, the results showed that 23 of the 32 pathogenic *E. coli* strains produced yellow halos with different diameters around the bacterial growth, indicating siderophores production, whereas 9 *E. coli* strains failed to

Table 4. Antibiotic susceptibility of the plasmid-cured and plasmid-transformed *E. coli* strains according to CLSI (2019)

Bacterial strains	Chemical group of antibiotics																		
	Aminoglycoside		Ansa-mycins	β-lactams			Cephems									Glyco-peptides	Quinolones		Sulfo-namide
	GMN_{10}	KAN	RD_5	AMP_{10}	AML_{10}	P_{10}	FOX_{30}	CL_{30}	CRO_{30}	CFM_5	CEC_{30}	CFP_{75}	CFR_{30}	$CFS_{75/30}$	CXM_{30}	VA_{30}	NOR_{10}	OFX_5	SXT_{25}
DH5α	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
21	S	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
DH5α (21)	S	S	S	R	R	R	R	R	R	R	R	R	R	R	R	S	S	S	S
49	R	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
DH5α (49)	S	S	S	R	R	R	R	R	R	R	R	R	R	R	R	R	S	S	S
49 (cured)	S	S	S	I	I	I	S	S	S	S	S	S	S	I	S	S	S	S	S

S – sensitive, I – intermediate, R – resistant

grow on the CAS agar medium. The quantitative detection of siderophores was first performed according to the method of Schwyn and Neilands (1987) by using the CAS assay solution, and it was observed that, after mixing piperazine-HCl buffer solution with the CAS dye indicator solution, the blue CAS dye precipitated after a short period. This problem was also reported by Alexander and Zuberer (1991). To overcome this issue, the CAS assay solution medium was freshly prepared just before the beginning of the assay; however, it also yielded varying absorbance of reference solution (Ar), and consequently, inconsistent results were obtained using this procedure. In contrast, after using the modified CAS assay solution method of Alexander and Zuberer (1991), it was observed that the substitution of piperazine-HCL buffer with MES buffer resulted in stable blue CAS dye, and consistent results was obtained. Alexander and Zuberer (1991) also reported that bacteria that failed to produce siderophores on CAS agar often produced siderophores in a liquid medium with limited iron concentration that could be measured with the modified CAS assay solution. This was also observed in the present study, as 7 strains failed to produce siderophores on CAS agar but produced them in a liquid M9 medium at concentrations measured with the modified CAS assay solution. This could be attributed to the toxicity of hexadecyltrimethylammonium bromide (HDTMA) to some bacterial strains as reported by Alexander and Zuberer (1991). In contrast, other strains failed to produce siderophores in the M9 medium, although they produced a yellow halo on CAS agar. This could be because the growth and amount of siderophores produced by an organism under different culture conditions are different (McRose et al., 2017; McRose et al., 2018; Armin et al., 2021; Kang-Yun et al., 2021)

Although the genes responsible for regulating siderophores are located on the chromosome (Thode et al., 2018; Massip and Oswald, 2020), it has been reported that the genes responsible for siderophores production were originally plasmid encoded (Faoro et al., 2019; Sarowska et al., 2019; Choby et al., 2020; Heiden et al., 2020) .

In the present study, four plasmid-cured strains derived from *E. coli* strain 49 failed to grow on both CAS agar and M9 media, and no siderophores were detected using the modified CAS assay solution. These results might indicate that the siderophores-encoding genes are located on the plasmid rather than on chromosomal DNA. However, *E. coli* strain DH5α transformed with

the plasmids obtained from *E. coli* strains 21 and 49 failed to produce siderophores. This could be because the iron assimilation system in bacteria and fungi is regulated by the chromosomal *fur* (ferric uptake regulation) gene product, a universal iron assimilation system regulator in *E. coli* and other bacteria (Klebba et al., 2021; Seyoum et al., 2021). The *fur* gene product (fur protein) acts as a negative repressor for siderophores transcription (Pi and Helmann, 2018; Bradley et al., 2020; Santos et al., 2020). In particular, the *E. coli* fur protein is a 17 kDa polypeptide that under iron-rich conditions binds the divalent ion (Fe^{2+}) and binds to target sequences or the recognition site (generally designated as the fur box or iron box with the assent sequence $5'-GATAATGATAATCATTATC-3'$) and inhibits transcription wherein all genes for siderophores biosynthesis are repressed by the metal (Parveen et al., 2019; Doni et al., 2020). In contrast, under iron-limited condition, all genes for siderophores biosynthesis are expressed, where Fe^{2+} is released and subsequently, the fur protein acquires a configuration wherein it cannot bind to the fur box; consequently, RNA polymerase starts the transcription of genes for siderophores biosynthesis (Zhang et al., 2020).

Screening of plasmid-cured mutants derived from *E. coli* strain 49 for antibiotic susceptibility showed that these colonies were susceptible to all the tested antibiotics, indicating that the resistance to these antibiotics is plasmid encoded. However, *E. coli* strain DH5α transformed with the plasmid isolated from *E. coli* strain 49 acquired resistance only to β-lactams and cephems. It is likely that some regulators encoded by the chromosomal materials of *E. coli* strain 49 act as activators (switching on) for the genes responsible for resistance against the remaining antibiotic groups. These regulators could be absent in *E. coli* DH5α (Banda et al., 2019; Jung et al., 2021).

The obtained results suggest the presence of a positive correlation between antibiotic resistance and siderophores production in the tested *E. coli* strains. A similar finding was reported in an analogous study, where an apparent association was observed between increased resistance to fluoroquinolones and siderophores production in 55 strains of *Enterococcus* (Lisiecki, 2013).

In the literature, the majority of work on the relationship between the presence of different virulence factors and antibiotic resistance indicates a positive link between them. However, because little is known about the type and extent of this relationship, future studies are required to investigate this point.

Conclusions

The present study provides data on siderophores production and the antibiotic susceptibility pattern of 32 clinical *E. coli* strains collected from different clinical settings in Cairo, Egypt. The obtained results revealed that 31 strains could be considered as XDR and only one strain was PDR. Furthermore, 23 *E. coli* strains produced siderophores, whereas 9 strains failed to do so. *E. coli* strains 21 and 49 were found to be the most potent siderophores producers. The identity of the two strains was further confirmed by a molecular approach. The role of siderophores production in antibiotic resistance of these two strains was also investigated. Plasmid-cured bacterial colonies derived from strain 49 were susceptible to all the tested antibiotics. *E. coli* DH5α cells transformed with the plasmid isolated from *E. coli* strain 21 or strain 49 were susceptible to ansamycins, quinolones, and sulfonamides. In contrast, both plasmid-cured and plasmid-transformed strains did not produce siderophores, indicating that the genes responsible for siderophores production could be located on plasmids and regulated by genes located on the chromosome. The findings of the present study suggest a positive correlation between antibiotic resistance, especially to quinolones and sulfonamides, and siderophores production by the *E. coli* strains tested in this study.

References

Abdallah H.M., Wintermans B.B., Reuland E.A., Koek A., Naiemi N., Al Ammar A.M., Mohamed A.A., Vandenbroucke-Grauls C.M.J.E. (2015) *Extended-spectrum β-lactamase- and carbapenemase-producing enterobacteriaceae isolated from Egyptian patients with suspected blood stream infection.* PLoS One. 10(5): e0128120. https://doi.org/10.1371/journal.pone.0128120

Adamus-Bialek W., Zajac E., Parniewski P., Kaca W. (2013) *Comparison of antibiotic resistance patterns in collections of Escherichia coli and Proteus mirabilis uropathogenic strains.* Mol. Biol. Rep. 40(4): 3429–3435.

Adefisoye M.A., Okoh A.I. (2016) *Identification and antimicrobial resistance prevalence of pathogenic Escherichia coli strains from treated wastewater effluents in Eastern Cape, South Africa.* Microbiologyopen. 5(1): 143–151. https://doi.org/10.1002/mbo3.319

Ahmed E., Holmström S.J.M. (2014) *Siderophores in environmental research: roles and applications.* Microb. Biotechnol. 7(3): 196–208. https://doi.org/10.1111/1751-7915.12117

Alexander D.B., Zuberer D.A. (1991) *Use of chrome azurol S reagents to evaluate siderophore production by rhizosphere bacteria.* Biol. Fertil. Soils. 12(1): 39–45.

Ali I., Kumar N., Ahmed S., Dasti J.I. (2014) *Antibiotic resistance in uropathogenic E. coli strains isolated from non-hospitalized patients in Pakistan.* J. Clin. Diagnostic Res. J.C.D.R. 8(9): DC01.

Altschul S.F., Gish W., Miller W., Myers E.W., Lipman D.J. (1990) *Basic local alignment search tool.* J. Mol. Biol. 215(3): 403–410.

Armin R., Zühlke S., Grunewaldt-Stöcker G., Mahnkopp-Dirks F., Kusari S. (2021) *Production of siderophores by an apple root-associated streptomyces ciscaucasicus strain gs2 using chemical and biological osmac approaches.* Molecules 26(12): 3517. https://doi.org/10.3390/molecules26123517.

Banda M.M., Manzo R., Bustamante V.H. (2019) *HilD induces expression of a novel Salmonella Typhimurium invasion factor, YobH, through a regulatory cascade involving SprB.* Sci. Rep. 9(1): 12725. https://doi.org/10.1038/s41598-019-49192-z

Bashir S., Haque A., Sarwar Y., Ali A., Anwar M.I. (2012) *Virulence profile of different phylogenetic groups of locally isolated community acquired uropathogenic E. coli from Faisalabad region of Pakistan.* Ann. Clin. Microbiol. Antimicrob. 11(1): 1.

Bauer A.W., Kirby W.M.M., Sherris J.C., Turck A.M., Graevenitz A. Von. (1966) *Antibiotic susceptibility testing by a standardized single disk method.* Am. J. Clin. Pathol. 45(4): 493–496.

Belanger L., Garenaux A., Harel J., Boulianne M., Nadeau E., Dozois C.M. (2011) *Escherichia coli from animal reservoirs as a potential source of human extraintestinal pathogenic E. coli.* F.E.M.S Immunol. Med. Microbiol. 62(1): 1–10. https://doi.org/10.1111/j.1574-695X.2011.00797.x

Bimboim H.C., Doly J. (1979) *A rapid alkaline extraction procedure for screening recombinant plasmid DNA.* Nucl. Acids Res. 7(6): 1513–1523. https://doi.org/10.1093/nar/7.6.1513

Bodendoerfer E., Marchesi M., Imkamp F., Courvalin P., Böttger E.C., Mancini S. (2020) *Co-occurrence of aminoglycoside and β-lactam resistance mechanisms in aminoglycoside- non-susceptible Escherichia coli isolated in the Zurich area, Switzerland.* Int. J. Antimicrob. Agents. 56(1): 106019. https://doi.org/10.1016/j.ijantimicag.2020.106019

Bradley J.M, Svistunenko D.A., Wilson M.T., Hemmings A.M., Moore G.R., Le Brun N.E. (2020) *Bacterial iron detoxification at the molecular level.* J. Biol. Chem. 295(51): 17602–17623. https://doi.org/10.1074/jbc.REV120.007746

Chakrawarti A., Dongol P., Khanal H., Subba P., Benerjee J.J. (2015) *Extended spectrum beta lactamases detection and multiple antibiotic resistance indexing of Escherichia coli from urine samples of patients from a referral hospital of Eastern Nepal.* Int. J. Appl. Sci. Biotechnol. 3: 423. https://doi.org/10.3126/ijasbt.v3i3.12924; http://www.nepjol.info/index.php/IJASBT/article/view/12924

Choby J.E., Howard-Anderson J., Weiss D.S. (2020) *Hypervirulent Klebsiella pneumoniae – clinical and molecular perspectives.* J. Intern. Med. 287(3): 283–300. https://doi.org/10.1111/joim.13007

Church N.A., McKillip J.L. (2021) *Antibiotic resistance crisis: challenges and imperatives.* Biologia (Bratisl). 76(5): 1535–1550. https://doi.org/10.1007/s11756-021-00697-x

CLSI (2019) *CLSI M100-ED29: 2019 Performance Standards for Antimicrobial Susceptibility Testing*, 29th Edition.

da Silva G.J., Mendonça N. (2012) *Association between antimicrobial resistance and virulence in Escherichia coli*. Virulence 3(1): 18–28.

Doni D., Passerini L., Audran G., Marque S.R., Schulz M., Santos J., Carbonera D. (2020) *Effects of Fe2+/Fe3+ binding to human frataxin and its D122Y variant, as revealed by site-directed spin labeling (SDSL) EPR complemented by fluorescence and circular dichroism spectroscopies*. Intern. J. Mol. Sci. 21(24): 9619.

Dromigny J.A., Nabeth P., Juergens-Behr A., Perrier-Gros-Claude J.D. (2005) *Risk factors for antibiotic-resistant Escherichia coli isolated from community-acquired urinary tract infections in Dakar, Senegal*. J. Antimicrob. Chemother. 56(1): 236–239.

Drummond A.J., Ashton B., Buxton S., Cheung M., Heled J., Kearse M., Moir R.S-HS., Thierer T.WA. (2014) Geneious v4.8.

Edgar R.C. (2004) *MUSCLE: multiple sequence alignment with high accuracy and high throughput*. Nucl. Acids Res. 32(5): 1792–1797.

El Kholy A., Baseem H., Hall G.S., Procop G.W., Longworth D.L. (2003) *Antimicrobial resistance in Cairo, Egypt 1999––2000: a survey of five hospitals*. J. Antimicrob. Chemother. 51(3): 625–630. https://doi.org/10.1093/jac/ dkg101

Emerson D., Roden E., Twining B.S. (2012) *The microbial ferrous wheel: Iron cycling in terrestrial, freshwater, and marine environments*. Front. Microbiol. 31(3): 383. https://doi.org/10.3389/fmicb.2012.00383

Fahim N.A.E. (2021) *Prevalence and antimicrobial susceptibility profile of multidrug-resistant bacteria among intensive care units patients at Ain Shams University Hospitals in Egypt–a retrospective study*. J. Egypt Public Health Assoc. 96(1): 7. https://doi.org/1.1186/s42506-020-00065-8

Faoro H., Oliveira W.K., Weiss V.A., Tadra-Sfeir M.Z., Cardoso R.L., Balsanelli E., Brusamarello-Santos L.C.C., Camilios-Neto D., Cruz L.M., Raittz R.T. et al. (2019) *Genome comparison between clinical and environmental strains of Herbaspirillum seropedicae reveals a potential new emerging bacterium adapted to human hosts*. B.M.C Genomics. 20(1): 630. https://doi.org/10.1186/s12864-019-5982-9

Garénaux A., Caza M., Dozois C.M. (2011) *The ins and outs of siderophore mediated iron uptake by extra-intestinal pathogenic Escherichia coli*. Vet. Microbiol. 153(1): 89–98.

Gashe F., Mulisa E., Mekonnen M., Zeleke G. (2018) *Antimicrobial resistance profile of different clinical isolates against third-generation cephalosporins*. J. Pharm. 2018: 5070742. https://doi.org/10.1155/2018/5070742

Heiden S.E., Hübner N.O., Bohnert J.A., Heidecke C.D., Kramer A., Balau V., Gierer W., Schaefer S., Eckmanns T., Gatermann S. et al. (2020) *A Klebsiella pneumoniae ST307 outbreak clone from Germany demonstrates features of extensive drug resistance, hypermucoviscosity, and enhanced iron acquisition*. Genome Med. 12: 113. https://doi.org/10.1186/s13073-020-00814-6

Hennequin C., Robin F. (2016) *Correlation between antimicrobial resistance and virulence in Klebsiella pneumoniae*. Eur. J. Clin. Microbiol. Infect. Dis. 35(3): 333–341. https://doi.org/10.1007/s10096-015-2559-7; https://www.ncbi.nlm.nih.gov/pubmed/26718943

Holden V.I., Bachman M.A. (2015) *Diverging roles of bacterial siderophores during infection*. Metallomics. 7(6): 986–995. https://doi.org/10.1039/c4mt00333k

Jacoby G.A. (2005) *Mechanisms of resistance to quinolones*. Clin. Infect. Dis. 41(suppl. 2): S120–S126.

Jung D., Park S., Ruffini J., Dussault F., Dufour S., Ronholm J. (2021) *Comparative genomic analysis of Escherichia coli isolates from cases of bovine clinical mastitis identifies nine specific pathotype marker genes*. Microb. Genom. 7(7): 000597. https://doi.org/10.1099/MGEN.0.000597

Kakoullis L., Papachristodoulou E., Chra P., Panos G. (2021) *Mechanisms of antibiotic resistance in important gram-positive and gram-negative pathogens and novel antibiotic solutions*. Antibiotics 10(4): 415. https://doi.org/10.3390/antibiotics10040415

Kang-Yun C.S., Liang X., Dershwitz P., Gu W., Schepers A., Flatley A., Lichtmannegger J., Zischka H., Zhang L., Lu X., et al. (2021) *Evidence for methanobactin "Theft" and novel chalkophore production in methanotrophs: impact on methanotrophic-mediated methylmercury degradation*. ISME J. 16: 211–220. https://doi.org/10.1038/s41396-021-01062-1

Khalifa H.O., Soliman A.M., Ahmed A.M., Shimamoto Toshi, Nariya H., Matsumoto T., Shimamoto Tadashi. (2019) *High prevalence of antimicrobial resistance in gram-negative bacteria isolated from clinical settings in Egypt: recalling for judicious use of conventional antimicrobials in developing nations*. Microb. Drug. Resist. 25(3): 371–385. https://doi.org/10.1089/mdr.2018.0380

Kiffer C.R., Mendes C., Oplustil C.P., Sampaio J.L. (2007) *Antibiotic resistance and trend of urinary pathogens in general outpatients from a major urban city*. Int. Braz. J. Urol. 33(1): 42–49.

Klebba P.E., Newton S.M.C., Six D.A., Kumar A., Yang T., Nairn B.L., Munger C., Chakravorty S. (2021) *Iron acquisition systems of gram-negative bacterial pathogens define TonB-dependent pathways to novel antibiotics*. Chem. Rev. 121(9): 5193–5239. https://doi.org/10.1021/acs.chemrev.0c01005

Kramer J., Özkaya Ö., Kümmerli R. (2020) *Bacterial siderophores in community and host interactions*. Nat. Rev. Microbiol. 18(3): 152–163. https://doi.org/10.1038/s41579-019-0284-4

Kronvall G. (2010) *Antimicrobial resistance 1979–2009 at Karolinska hospital, Sweden: normalized resistance interpretation during a 30 year follow up on Staphylococcus aureus and Escherichia coli resistance development*. APMIS 118(9): 621–639.

Leimbach A., Hacker J., Dobrindt U. (2013) *E. coli as an all-rounder: the thin line between commensalism and pathogenicity*. [in:] *Between pathogenicity and commensalism*. Springer: 3–32.

Leski T.A., Stockelman M.G., Bangura U., Chae D., Ansumana R., Stenger D.A., Vora G.J., Taitt C.R. (2016) *Prevalence of quinolone resistance in Enterobacteriaceae from Sierra Leone and the detection of qnrB pseudogenes and modified*

LexA binding sites. Antimicrob. Agents Chemother. 60(11): 6920–6923. https://doi.org/10.1128/AAC.01576-16

Lin W.P., Huang Y.S., Wang J.T., Chen Y.C., Chang S.C. (2019) *Prevalence of and risk factor for community-onset third-generation cephalosporin-resistant Escherichia coli bacteremia at a medical center in Taiwan.* BMC Infect. Dis. 19(1): 245. https://doi.org/10.1186/s12879-019-3880-z

Lisiecki P. (2013) *Antibiotic resistance and siderophore production in enterococci.* Med. Dosw. Mikrobiol. 66(1): 1–10.

Ma F., Xu S., Tang Z., Li Z., Zhang L. (2021) *Use of antimicrobials in food animals and impact of transmission of antimicrobial resistance on humans.* Biosaf. Heal. 3(1): 32–38. https://doi.org/10.1016/j.bsheal.2020.09.004

Magiorakos A.-P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., Harbarth S., Hindler J.F. (2011) *Bacteria: an international expert proposal for interim standard definitions for acquired resistance.* Microbiology 18(3): 268–281. https://doi.org/10.1111/j.1469-0691.2011. 03570.x

Malekzadegan Y., Rastegar E., Moradi M., Heidari H., Ebrahim-Saraie H.S. (2019) *Prevalence of quinolone-resistant uropathogenic escherichia coli in a tertiary care hospital in south iran.* Infect. Drug. Resist. 12: 2175–2176. https://doi.org/10.2147/IDR.S206966

Malik B., Bhattacharyya S. (2019) *Antibiotic drug-resistance as a complex system driven by socio-economic growth and antibiotic misuse.* Sci. Rep. 9(1): 9788. https://doi.org/10.1038/s41598-019-46078-y

Maniatis T., Fritsch E.F., Sambrook J. (1982) *Molecular cloning: a laboratory manual.* Cold Spring Harbor Lab. Press, New York.

Massip C., Oswald E. (2020) *Siderophore-microcins in Escherichia coli: determinants of digestive colonization, the first step toward virulence.* Front. Cell. Infect. Microbiol. 10: 381. https://doi.org/10.3389/fcimb.2020.00381

Mathlouthi N., Al-Bayssari C., El Salabi A., Bakour S., Gwierif S. Ben., Zorgani A.A., Jridi Y., Slama K. Ben., Rolain J.-M., Chouchani C. (2016) *Carbapenemases and extended-spectrum β-lactamases producing Enterobacteriaceae isolated from Tunisian and Libyan hospitals.* J. Infect. Dev. Ctries. 10(07): 718–727.

McRose D.L., Baars O., Morel F.M.M., Kraepiel A.M.L. (2017) *Siderophore production in Azotobacter vinelandii in response to Fe-, Mo- and V-limitation.* Environ. Microbiol. 19(9): 3595–3605. https://doi.org/10.1111/1462-2920.13857

McRose D.L., Seyedsayamdost M.R., Morel F.M.M. (2018) *Multiple siderophores: bug or feature?* J. Biol. Inorg. Chem. 23(7): 983–993. https://doi.org/10.1007/s00775-018-1617-x

Moroh J.-L., Fleury Y., Tia H., Bahi C., Lietard C., Coroller L., Edoh V., Coulibaly A., Labia R., Leguerinel I. (2014) *Diversity and antibiotic resistance of uropathogenic bacteria from Abidjan.* African. J. Urol. 20(1): 18–24.

Parveen S., Bishai W.R., Murphy J.R. (2019) *Corynebacterium diphtheriae: diphtheria toxin, the tox Operon, and its regulation by Fe2+ activation of apo-DtxR.* Microbiol. Spectrum 7(4): 7–14.

Paterson D.L. (2006) *Resistance in gram-negative bacteria: Enterobacteriaceae.* Am. J. Med. 119(6): S20–S28.

Pi H., Helmann J.D. (2018) *Genome-wide characterization of the fur regulatory network reveals a link between catechol degradation and bacillibactin metabolism in bacillus subtilis.* mBio 9(5): e01451-18. https://doi.org/10.1128/mbio. 01451-18

Pi H., Jones S.A., Mercer L.E., Meador J.P., Caughron J.E., Jordan L., Newton S.M., Conway T., Klebba P.E. (2012) *Role of catecholate siderophores in gram-negative bacterial colonization of the mouse gut.* PLoS One 7(11): e50020.

Pitout J. (2012) *Extraintestinal pathogenic Escherichia coli: a combination of virulence with antibiotic resistance.* Front. Microbiol. 3: 9.

Pondei K., Oladapo O., Kunle-Olowu O.E. (2012) *Anti-microbial susceptibility pattern of micro-organisms associated with urinary tract infections in a tertiary health institution in the Niger Delta Region of Nigeria.* African. J. Microbiol. Res. 6(23): 4976–4982.

Prasada S., Bhat A., Bhat S., Mulki S.S., Tulasidas S. (2019) *Changing antibiotic susceptibility pattern in uropathogenic escherichia coli over a period of 5 years in a tertiary care center.* Infect. Drug. Resist. 12: 1439–1443. https://doi.org/10.2147/IDR.S201849

Ramirez M.S., Traglia G.M., Lin D.L., Tran T., Tolmasky M.E. (2014) *Plasmid-mediated antibiotic resistance and virulence in Gram-negatives: the Klebsiella pneumoniae paradigm.* Microbiol. Spectr. 2(5): 1.

Rath S., Padhy R.N. (2015) *Prevalence of fluoroquinolone resistance in Escherichia coli in an Indian teaching hospital and adjoining communities.* J. Taibah. Univ. Med. Sci. 10(4): 504–508.

Sabtu N., Enoch D.A, Brown N.M. (2015) *Antibiotic resistance: what, why, where, when and how?* Br. Med. Bull. 116(1): 105–113. https://doi.org/10.1093/bmb/ldv041

Saha M., Sarkar S., Sarkar B., Sharma B.K., Bhattacharjee S., Tribedi P. (2016) *Microbial siderophores and their potential applications: a review.* Environ. Sci. Pollut. Res. 23(5): 3984–3999.

Saitou N., Nei M. (1987) *The neighbor-joining method: a new method for reconstructing phylogenetic trees.* Mol. Biol. Evol. 4(4): 406–425.

Sambrook J., Fritsch E.F., Maniatis T. (1989) *Molecular cloning.* New York. Cold Spring Harbor Laboratory Press 2: 14–19.

De Souza Santos R.E.R., Batista B.B., da Silva Neto. J.F. (2020) *Ferric uptake regulator Fur coordinates siderophore production and defense against iron toxicity and oxidative stress and contributes to virulence in Chromobacterium violaceum.* Appl. Environ. Microbiol. 86(21): e01620-20. https://doi.org/10.1128/AEM.01620-20

Sarowska J., Futoma-Koloch B., Jama-Kmiecik A., Frej-Madrzak M., Ksiazczyk M., Bugla-Ploskonska G., Choroszy-Krol I. (2019) *Virulence factors, prevalence and potential transmission of extraintestinal pathogenic Escherichia coli isolated from different sources: recent reports.* Gut. Pathog. 11(1): 10. https://doi.org/10.1186/s13099-019-0290-0

Schwyn B., Neilands J.B. (1987) *Universal chemical assay for the detection and determination of siderophores.* Anal. Biochem. 160(1): 47–56.

Searle L.J., Méric G., Porcelli I., Sheppard S.K., Lucchini S. (2015) *Variation in siderophore biosynthetic gene distribution and production across environmental and faecal populations of Escherichia coli*. PLoS One 10: 1–14. https://doi.org/10.1371/journal.pone.0117906

Seyoum Y., Baye K., Humblot C. (2021) *Iron homeostasis in host and gut bacteria–a complex interrelationship*. Gut. Microbes. 13(1): 1–19. https://doi.org/10.1080/19490976.2021.1874855

Shanahan P.M.A., Wylie B.A., Adrian P.V., Koornhof H.J., Thomson C.J., Amyes S.G.B. (1993) *The prevalence of antimicrobial resistance in human faecal flora in South Africa*. Epidemiol. Infec. 111: 221–228.

Tadesse D.A., Zhao S., Tong E., Ayers S., Singh A., Bartholomew M.J., McDermott P.F. (2012) *Antimicrobial drug resistance in Escherichia coli from humans and food animals, United States, 1950–2002*. Emerg. Infect. Dis. 18(5): 741–749. https://doi.org/10.3201/eid1805.111153

Tajbakhsh E., Ahmadi P., Abedpour-Dehkordi E., Arbab-Soleimani N., Khamesipour F. (2016) *Biofilm formation, antimicrobial susceptibility, serogroups and virulence genes of uropathogenic E. coli isolated from clinical samples in Iran*. Antimicrob. Resist. Infect. Control. 5(1): 1.

Tamura K., Nei M. (1993) *Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees*. Mol. Biol. Evol. 10(3): 512–526.

Thode S.K., Rojek E., Kozlowski M., Ahmad R., Haugen P. (2018) *Distribution of siderophore gene systems on a Vibrionaceae phylogeny: Database searches, phylogenetic analyses and evolutionary perspectives*. PLoS One 13(2): e0191860. https://doi.org/10.1371/journal.pone.0191860

Trevors J.T. (1986) *Plasmid curing in bacteria*. FEMS. Microbiol. Lett. 1(3–4): 149–157. https://doi.org/10.1016/0378-1097(86)90286-7

Vagrali M.A. (2009) *Siderophore production by uropathogenic Escherichia coli*. Indian. J. Pathol. Microbiol. 52(1): 126.

Van Der Steen M., Leenstra T., Kluytmans J.A.J.W., Van Der Bij A.K. (2015) *Trends in expanded-spectrum cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae among Dutch clinical isolates, from 2008 to 2012*. PLoS One 10(9): e0138088. https://doi.org/10.1371/journal.pone.0138088

Von Baum H., Marre R. (2005) *Antimicrobial resistance of Escherichia coli and therapeutic implications*. Int. J. Med. Microbiol. 295(6–7): 503–511. https://doi.org/10.1016/j.ijmm.2005.07.002

Wang Y., Zhao S., Han L., Guo X., Chen M., Ni Y., Zhang Y., Cui Z., He P. (2014) *Drug resistance and virulence of uropathogenic Escherichia coli from Shanghai, China*. J. Antibiot. (Tokyo). 67(12): 799–805. https://doi.org/10.1038/ja.2014.72; http://dx.doi.org/10.1038/ja.2014.72

Woo B., Jung Y., Kim H.S. (2019) *Antibiotic sensitivity patterns in children with urinary tract infection: retrospective study over 8 years in a single center*. Child. Kidney Dis. 23(1): 22–28. https://doi.org/10.3339/jkspn.2019.23.1.22

Zhang F., Li B., Dong H., Chen M., Yao S., Li J., Zhang H., Liu X., Wang H., Song N., et al. (2020) *YdiV regulates Escherichia coli ferric uptake by manipulating the DNA-binding ability of Fur in a SlyD-dependent manner*. Nucl. Acids Res. 48(17): 9571–9588. https://doi.org/10.1093/nar/gkaa696